# HLP004 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/hlp004

> The next catalyst for HLP004, sponsored by Helus Pharma Inc. (HELP), is its trial start, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for HLP004?

The next catalyst for HLP004, sponsored by Helus Pharma Inc. (HELP), is its trial start, Q1 2027. Press release filed with the SEC (EX-99): "The Company expects to spend approximately $6,329 to initiate a Phase 2 monotherapy study by the end of Q1 2027.16 No amounts were spent toward the achievement of this milestone during the six months ended September 30, 2026." [Calendar and source filings](https://sec-api.dev/pdufa/hlp004)

Source: Press release filed with the SEC (EX-99), accession 0001833141-26-000100, https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm (retrieved 2026-11-13). Last confirmed 2026-11-13. Cite: https://sec-api.dev/pdufa/hlp004#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | HLP004 |
| Codes | HLP004 |
| Sponsor | Helus Pharma Inc. (HELP) https://sec-api.dev/companies/help/catalysts |
| Indications | [moderate to severe gad](https://sec-api.dev/indications/moderate-to-severe-gad), generalized anxiety disorder, with phase 2 topline data readout |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### January 8, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 1.
- First seen 2026-02-13, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000100): "On January 8, 2024, the Company announced positive topline results from its Phase 1 studies of its proprietary molecules, HLP004 and SPL028." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000058): "On January 8, 2024, the Company announced positive topline results from its Phase 1 studies of its proprietary molecules, HLP004 and SPL028." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000058/cybin-mdaxq1x27.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000012): "On January 8, 2024, the Company announced positive topline results from its Phase 1 studies of its proprietary molecules, HLP004 and SPL028." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000012/cybin-mdaxq3x26.htm

### March 15, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 2. Indication: moderate to severe GAD.
- First seen 2026-02-13, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000100): "On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM HLP004 in participants with moderate to severe GAD." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000058): "On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM HLP004 in participants with moderate to severe GAD." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000058/cybin-mdaxq1x27.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000012): "On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM HLP004 in participants with moderate to severe GAD." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000012/cybin-mdaxq3x26.htm

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: generalized anxiety disorder, with Phase 2 topline data readout.
- First seen 2026-01-05, last confirmed 2026-02-17.
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000014): "•Findings reinforce the therapeutic potential of short-acting serotonergic agonists and inform Helus Pharma's HLP004 development program, with Phase 2 topline data in generalized anxiety disorder ("GAD") expected in Q1 2026" https://www.sec.gov/Archives/edgar/data/1833141/000183314126000014/naturemedicinedmtpressrele.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000012): "- Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder ("GAD") expected in Q1 2026 -" https://www.sec.gov/Archives/edgar/data/1833141/000183314126000012/q3earningspr2026.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000012): "•Anticipated topline data readout from the Phase 2 study evaluating HLP004 in GAD in Q1 2026." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000012/q3earningspr2026.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000012): "the Company's anticipated topline data readout from the Phase 2 study evaluating HLP004 in GAD in Q1 2026" https://www.sec.gov/Archives/edgar/data/1833141/000183314126000012/q3earningspr2026.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000002): "•Helus Pharma continues to progress its portfolio of novel serotonergic agonists ("NSAs"), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026" https://www.sec.gov/Archives/edgar/data/1833141/000183314126000002/helusrebrandprfinal.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-02-10, last confirmed 2026-02-10.
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000006): "Mr. Cola's appointment comes at a pivotal moment as Helus advances its pipeline of next-generation mental health therapies toward key clinical and corporate value-inflection milestones, including the expected release of Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 in Q4 2026." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000006/helusceopressreleasedraft-.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000006): "Forward-looking statements in this news release include statements regarding the Company's expectation to meaningfully advance the treatment of serious mental health disorders; the ability of the Company's NSAs to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions; the release Phase 2 data for HLP004 in the first quarter of 2026 and Phase 3 topline data for HLP003 in the fourth quarter of 2026; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000006/helusceopressreleasedraft-.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000006): "•Appointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 later this year" https://www.sec.gov/Archives/edgar/data/1833141/000183314126000006/helusceopressreleasedraft-.htm

### Q1 2027: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-11-13, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000100): "The Company expects to spend approximately $6,329 to initiate a Phase 2 monotherapy study by the end of Q1 2027.16 No amounts were spent toward the achievement of this milestone during the six months ended September 30, 2026." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm

## Same indication

- [CYB004](https://sec-api.dev/pdufa/cyb004) (HELP)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/hlp004.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HLP004 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/hlp004

```bibtex
@misc{secapidev_pdufa_hlp004_20261116,
  title        = {HLP004 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/hlp004}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_hlp004_20261116","title":"HLP004 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/hlp004","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
